NCT04697290 - CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

June 10, 2023

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

CD19/CD20 Dual-CAR-T cells

CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 2E6、6E6、1E7、3E7 cells/kg.

Trial Locations (1)

Unknown

Beijing Tsinghua Changgung Hospital, Beijing